Related Experiment Video

Updated: Jun 4, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt

Noritaka Tanaka1, Hiromichi Ebi1,2

  • 1Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Japan.

Cancer Science
|December 27, 2024
PubMed

Insights

Targeting KRAS mutations shows promise, but resistance limits effectiveness. Understanding KRAS resistance mechanisms, including cellular rewiring and genetic alterations, is key to developing more effective cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • KRAS was historically considered undruggable, but targeted inhibitors exploiting the switch-II pocket are now available.
  • Despite clinical use, KRAS inhibitors face resistance, limiting long-term treatment efficacy.
  • Tumor progression involves shifts to alternative pathways and cellular rewiring, contributing to intrinsic and acquired resistance.

Purpose of the Study:

  • To elucidate the multifaceted resistance mechanisms against KRAS inhibitors.
  • To explore genetic and nongenetic alterations that confer resistance to KRAS-targeted therapies.
  • To identify strategies for overcoming KRAS inhibitor resistance in cancer treatment.

Main Methods:

  • Review of current literature on KRAS inhibitor resistance mechanisms.
  • Analysis of genetic alterations (e.g., secondary KRAS mutations, KEAP1 mutations) and nongenetic alterations (e.g., EMT, YAP activation, cell identity changes).
  • Examination of signaling pathway reactivation (MAPK, AKT) and metabolic reprogramming post-KRAS inhibition.

Main Results:

  • Resistance arises from intrinsic mechanisms like EMT, YAP activation, and KEAP1 mutations, and acquired mechanisms including secondary KRAS mutations.
  • KRAS inhibition triggers cellular rewiring, such as MAPK/AKT reactivation and metabolic changes, to promote survival.
  • Cellular identity shifts and protein re-localization contribute to drug resistance by driving pathway reactivation.
  • Secondary mutations in the switch-II pocket or other oncogenic alterations impede drug binding and efficacy.

Conclusions:

  • Overcoming KRAS resistance requires strategies that enhance drug efficacy, target multiple pathways, and incorporate immune checkpoint inhibitors.
  • Developing broad-spectrum inhibitors and combination therapies is crucial for sustained therapeutic benefit.
  • Further research into KRAS resistance mechanisms will guide the development of next-generation KRAS-targeted treatments.
Keywords:
KRASlineage plasticitynongenetic mechanismresistancesecondary mutation

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.5K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K